Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 31 entries
Sorted by: Best Match Show Resources per page
Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia.

Nature clinical practice. Cardiovascular medicine

Vergeer M, Kastelein JJ.
PMID: 18431368
Nat Clin Pract Cardiovasc Med. 2008 Jun;5(6):302-3. doi: 10.1038/ncpcardio1190. Epub 2008 Apr 22.

No abstract available.

Cite
Vergeer M, Kastelein JJ. Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia. Nat Clin Pract Cardiovasc Med. 2008;5(6):302-3doi: 10.1038/ncpcardio1190.
Vergeer, M., & Kastelein, J. J. (2008). Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia. Nature clinical practice. Cardiovascular medicine, 5(6), 302-3. https://doi.org/10.1038/ncpcardio1190
Vergeer, Menno, and Kastelein, John J P. "Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia." Nature clinical practice. Cardiovascular medicine vol. 5,6 (2008): 302-3. doi: https://doi.org/10.1038/ncpcardio1190
Vergeer M, Kastelein JJ. Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia. Nat Clin Pract Cardiovasc Med. 2008 Jun;5(6):302-3. doi: 10.1038/ncpcardio1190. Epub 2008 Apr 22. PMID: 18431368.
Copy Download .nbib Format: NLM
Survival of Ralstonia solanacearum Biovar 2, the Causative Agent of Potato Brown Rot, in Field and Microcosm Soils in Temperate Climates.

Phytopathology

van Elsas JD, Kastelein P, van Bekkum P, van der Wolf JM, de Vries PM, van Overbeek LS.
PMID: 18943377
Phytopathology. 2000 Dec;90(12):1358-66. doi: 10.1094/PHYTO.2000.90.12.1358.

ABSTRACT After outbreaks of potato brown rot in three different fields in the Netherlands, the fate of the brown rot pathogen, Ralstonia solanacearum biovar 2, was monitored in soil by immunofluorescence colony staining (IFC) supported by R. solanacearum division-2...

Cite
van Elsas JD, Kastelein P, van Bekkum P, et al. Survival of Ralstonia solanacearum Biovar 2, the Causative Agent of Potato Brown Rot, in Field and Microcosm Soils in Temperate Climates. Phytopathology. 2000;90(12):1358-66doi: 10.1094/PHYTO.2000.90.12.1358.
van Elsas, J. D., Kastelein, P., van Bekkum, P., van der Wolf, J. M., de Vries, P. M., & van Overbeek, L. S. (2000). Survival of Ralstonia solanacearum Biovar 2, the Causative Agent of Potato Brown Rot, in Field and Microcosm Soils in Temperate Climates. Phytopathology, 90(12), 1358-66. https://doi.org/10.1094/PHYTO.2000.90.12.1358
van Elsas, J D, et al. "Survival of Ralstonia solanacearum Biovar 2, the Causative Agent of Potato Brown Rot, in Field and Microcosm Soils in Temperate Climates." Phytopathology vol. 90,12 (2000): 1358-66. doi: https://doi.org/10.1094/PHYTO.2000.90.12.1358
van Elsas JD, Kastelein P, van Bekkum P, van der Wolf JM, de Vries PM, van Overbeek LS. Survival of Ralstonia solanacearum Biovar 2, the Causative Agent of Potato Brown Rot, in Field and Microcosm Soils in Temperate Climates. Phytopathology. 2000 Dec;90(12):1358-66. doi: 10.1094/PHYTO.2000.90.12.1358. PMID: 18943377.
Copy Download .nbib Format: NLM
Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles.

Journal of the Endocrine Society

O'Dea LSL, MacDougall J, Alexander VJ, Digenio A, Hubbard B, Arca M, Moriarty PM, Kastelein JJP, Bruckert E, Soran H, Witztum JL, Hegele RA, Gaudet D.
PMID: 31777768
J Endocr Soc. 2019 Oct 11;3(12):2397-2410. doi: 10.1210/js.2019-00214. eCollection 2019 Dec 01.

CONTEXT: Differentiation between familial chylomicronemia syndrome (FCS, type 1 hyperlipoproteinemia), a rare metabolic disorder, and the more common multifactorial severe hypertriglyceridemia (sHTG, type 5 hyperlipoproteinemia) is challenging because of their overlapping symptoms but important in patient management.OBJECTIVE: To assess...

Cite
O'Dea LSL, MacDougall J, Alexander VJ, et al. Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. J Endocr Soc. 2019;3(12):2397-2410doi: 10.1210/js.2019-00214.
O'Dea, L. S. L., MacDougall, J., Alexander, V. J., Digenio, A., Hubbard, B., Arca, M., Moriarty, P. M., Kastelein, J. J. P., Bruckert, E., Soran, H., Witztum, J. L., Hegele, R. A., & Gaudet, D. (2019). Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. Journal of the Endocrine Society, 3(12), 2397-2410. https://doi.org/10.1210/js.2019-00214
O'Dea, Louis St L, et al. "Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles." Journal of the Endocrine Society vol. 3,12 (2019): 2397-2410. doi: https://doi.org/10.1210/js.2019-00214
O'Dea LSL, MacDougall J, Alexander VJ, Digenio A, Hubbard B, Arca M, Moriarty PM, Kastelein JJP, Bruckert E, Soran H, Witztum JL, Hegele RA, Gaudet D. Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. J Endocr Soc. 2019 Oct 11;3(12):2397-2410. doi: 10.1210/js.2019-00214. eCollection 2019 Dec 01. PMID: 31777768; PMCID: PMC6864364.
Copy Download .nbib Format: NLM
Beyond the Usual Suspects: Expanding on Mutations and Detection for Familial Hypercholesterolemia.

Expert review of molecular diagnostics

Ibrahim S, Defesche JC, Kastelein JJP.
PMID: 34263698
Expert Rev Mol Diagn. 2021 Sep;21(9):887-895. doi: 10.1080/14737159.2021.1953985. Epub 2021 Jul 21.

No abstract available.

Cite
Ibrahim S, Defesche JC, Kastelein JJP. Beyond the Usual Suspects: Expanding on Mutations and Detection for Familial Hypercholesterolemia. Expert Rev Mol Diagn. 2021;21(9):887-895doi: 10.1080/14737159.2021.1953985.
Ibrahim, S., Defesche, J. C., & Kastelein, J. J. P. (2021). Beyond the Usual Suspects: Expanding on Mutations and Detection for Familial Hypercholesterolemia. Expert review of molecular diagnostics, 21(9), 887-895. https://doi.org/10.1080/14737159.2021.1953985
Ibrahim, Shirin, et al. "Beyond the Usual Suspects: Expanding on Mutations and Detection for Familial Hypercholesterolemia." Expert review of molecular diagnostics vol. 21,9 (2021): 887-895. doi: https://doi.org/10.1080/14737159.2021.1953985
Ibrahim S, Defesche JC, Kastelein JJP. Beyond the Usual Suspects: Expanding on Mutations and Detection for Familial Hypercholesterolemia. Expert Rev Mol Diagn. 2021 Sep;21(9):887-895. doi: 10.1080/14737159.2021.1953985. Epub 2021 Jul 21. PMID: 34263698.
Copy Download .nbib Format: NLM
Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial.

JAMA cardiology

Nissen SE, Lincoff AM, Wolski K, Ballantyne CM, Kastelein JJP, Ridker PM, Ray KK, McGuire DK, Mozaffarian D, Koenig W, Davidson MH, Garcia M, Katona BG, Himmelmann A, Loss LE, Poole M, Menon V, Nicholls SJ.
PMID: 33993205
JAMA Cardiol. 2021 May 16; doi: 10.1001/jamacardio.2021.1157. Epub 2021 May 16.

IMPORTANCE: In patients treated with ω-3 fatty acids, it remains uncertain whether achieved levels of eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) are associated with cardiovascular outcomes.OBJECTIVE: To determine the association between plasma levels of EPA and DHA and...

Cite
Nissen SE, Lincoff AM, Wolski K, et al. Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. JAMA Cardiol. 2021;doi: 10.1001/jamacardio.2021.1157.
Nissen, S. E., Lincoff, A. M., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Ridker, P. M., Ray, K. K., McGuire, D. K., Mozaffarian, D., Koenig, W., Davidson, M. H., Garcia, M., Katona, B. G., Himmelmann, A., Loss, L. E., Poole, M., Menon, V., & Nicholls, S. J. (2021). Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. JAMA cardiology, . https://doi.org/10.1001/jamacardio.2021.1157
Nissen, Steven E, et al. "Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial." JAMA cardiology vol. (2021). doi: https://doi.org/10.1001/jamacardio.2021.1157
Nissen SE, Lincoff AM, Wolski K, Ballantyne CM, Kastelein JJP, Ridker PM, Ray KK, McGuire DK, Mozaffarian D, Koenig W, Davidson MH, Garcia M, Katona BG, Himmelmann A, Loss LE, Poole M, Menon V, Nicholls SJ. Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. JAMA Cardiol. 2021 May 16; doi: 10.1001/jamacardio.2021.1157. Epub 2021 May 16. PMID: 33993205; PMCID: PMC8126992.
Copy Download .nbib Format: NLM
Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.

Cardiovascular diagnosis and therapy

Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJ, Merkely B, Nissen SE, Ray K, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Butters J, Girardi J, Miller R, Nicholls SJ.
PMID: 28164012
Cardiovasc Diagn Ther. 2017 Feb;7(1):45-51. doi: 10.21037/cdt.2017.01.01.

BACKGROUND: High-density lipoprotein (HDL) is believed to have atheroprotective properties, but an effective HDL-based therapy remains elusive. Early studies have suggested that infusion of reconstituted HDL promotes reverse cholesterol transport and vascular reactivity. The CER-001 Atherosclerosis Regression Acute Coronary...

Cite
Andrews J, Janssan A, Nguyen T, et al. Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Cardiovasc Diagn Ther. 2017;7(1):45-51doi: 10.21037/cdt.2017.01.01.
Andrews, J., Janssan, A., Nguyen, T., Pisaniello, A. D., Scherer, D. J., Kastelein, J. J., Merkely, B., Nissen, S. E., Ray, K., Schwartz, G. G., Worthley, S. G., Keyserling, C., Dasseux, J. L., Butters, J., Girardi, J., Miller, R., & Nicholls, S. J. (2017). Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Cardiovascular diagnosis and therapy, 7(1), 45-51. https://doi.org/10.21037/cdt.2017.01.01
Andrews, Jordan, et al. "Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study." Cardiovascular diagnosis and therapy vol. 7,1 (2017): 45-51. doi: https://doi.org/10.21037/cdt.2017.01.01
Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJ, Merkely B, Nissen SE, Ray K, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Butters J, Girardi J, Miller R, Nicholls SJ. Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Cardiovasc Diagn Ther. 2017 Feb;7(1):45-51. doi: 10.21037/cdt.2017.01.01. PMID: 28164012; PMCID: PMC5253449.
Copy Download .nbib Format: NLM
Triglycerides and cardiovascular risk.

Current cardiology reviews

Harchaoui KE, Visser ME, Kastelein JJ, Stroes ES, Dallinga-Thie GM.
PMID: 20676280
Curr Cardiol Rev. 2009 Aug;5(3):216-22. doi: 10.2174/157340309788970315.

In 1996 a meta-analysis was published showing that an increase in plasma triglyceride (TG) levels was associated with an increase in CHD risk, even after adjustment for high density lipoprotein cholesterol (HDL-C) levels. Very recently, two studies were published...

Cite
Harchaoui KE, Visser ME, Kastelein JJ, et al. Triglycerides and cardiovascular risk. Curr Cardiol Rev. 2009;5(3):216-22doi: 10.2174/157340309788970315.
Harchaoui, K. E., Visser, M. E., Kastelein, J. J., Stroes, E. S., & Dallinga-Thie, G. M. (2009). Triglycerides and cardiovascular risk. Current cardiology reviews, 5(3), 216-22. https://doi.org/10.2174/157340309788970315
Harchaoui, K E L, et al. "Triglycerides and cardiovascular risk." Current cardiology reviews vol. 5,3 (2009): 216-22. doi: https://doi.org/10.2174/157340309788970315
Harchaoui KE, Visser ME, Kastelein JJ, Stroes ES, Dallinga-Thie GM. Triglycerides and cardiovascular risk. Curr Cardiol Rev. 2009 Aug;5(3):216-22. doi: 10.2174/157340309788970315. PMID: 20676280; PMCID: PMC2822144.
Copy Download .nbib Format: NLM
A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.

Journal of hepatology

Fraser DA, Wang X, Lund J, Nikolić N, Iruarrizaga-Lejarreta M, Skjaeret T, Alonso C, Kastelein JJP, Rustan AC, Kim YO, Schuppan D.
PMID: 34915054
J Hepatol. 2021 Dec 13; doi: 10.1016/j.jhep.2021.12.004. Epub 2021 Dec 13.

BACKGROUND AND AIMS: Although long-chain omega-3 fatty acids (LCn-3FAs) regulate inflammatory pathways of relevance to non-alcoholic steatohepatitis (NASH), their susceptibility to peroxidation may limit their therapeutic potential. We compared the metabolism of eicosapentaenoic acid (EPA) with an engineered EPA...

Cite
Fraser DA, Wang X, Lund J, et al. A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. J Hepatol. 2021;doi: 10.1016/j.jhep.2021.12.004.
Fraser, D. A., Wang, X., Lund, J., Nikolić, N., Iruarrizaga-Lejarreta, M., Skjaeret, T., Alonso, C., Kastelein, J. J. P., Rustan, A. C., Kim, Y. O., & Schuppan, D. (2021). A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. Journal of hepatology, . https://doi.org/10.1016/j.jhep.2021.12.004
Fraser, David A, et al. "A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH." Journal of hepatology vol. (2021). doi: https://doi.org/10.1016/j.jhep.2021.12.004
Fraser DA, Wang X, Lund J, Nikolić N, Iruarrizaga-Lejarreta M, Skjaeret T, Alonso C, Kastelein JJP, Rustan AC, Kim YO, Schuppan D. A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. J Hepatol. 2021 Dec 13; doi: 10.1016/j.jhep.2021.12.004. Epub 2021 Dec 13. PMID: 34915054.
Copy Download .nbib Format: NLM
Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091].

American journal of preventive cardiology

Nelson AJ, Puri R, Brennan DM, Anderson TJ, Cho L, Ballantyne CM, Kastelein JJ, Koenig W, Kassahun H, Somaratne RM, Wasserman SM, Nissen SE, Nicholls SJ.
PMID: 34374706
Am J Prev Cardiol. 2021 Feb 11;6:100153. doi: 10.1016/j.ajpc.2021.100153. eCollection 2021 Jun.

[This corrects the article DOI: 10.1016/j.ajpc.2020.100091.].

Cite
Nelson AJ, Puri R, Brennan DM, et al. Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]. Am J Prev Cardiol. 2021;6:100153doi: 10.1016/j.ajpc.2021.100153.
Nelson, A. J., Puri, R., Brennan, D. M., Anderson, T. J., Cho, L., Ballantyne, C. M., Kastelein, J. J., Koenig, W., Kassahun, H., Somaratne, R. M., Wasserman, S. M., Nissen, S. E., & Nicholls, S. J. (2021). Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]. American journal of preventive cardiology, 6100153. https://doi.org/10.1016/j.ajpc.2021.100153
Nelson, Adam J, et al. "Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]." American journal of preventive cardiology vol. 6 (2021): 100153. doi: https://doi.org/10.1016/j.ajpc.2021.100153
Nelson AJ, Puri R, Brennan DM, Anderson TJ, Cho L, Ballantyne CM, Kastelein JJ, Koenig W, Kassahun H, Somaratne RM, Wasserman SM, Nissen SE, Nicholls SJ. Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]. Am J Prev Cardiol. 2021 Feb 11;6:100153. doi: 10.1016/j.ajpc.2021.100153. eCollection 2021 Jun. PMID: 34374706; PMCID: PMC8315629.
Copy Download .nbib Format: NLM
Trypanosomatid parasites of plants (phytomonas).

Parasitology today (Personal ed.)

Camargo EP, Kastelein P, Roitman I.
PMID: 15463252
Parasitol Today. 1990 Jan;6(1):22-5. doi: 10.1016/0169-4758(90)90388-k.

Trypanosomatids of the genus Phytomonas have been known as parasites of lactiferous plants since the beginning of the century and have been the subject of renewed attention in the past decade, as they are now recognized to be pathogenic...

Cite
Camargo EP, Kastelein P, Roitman I. Trypanosomatid parasites of plants (phytomonas). Parasitol Today. 1990;6(1):22-5doi: 10.1016/0169-4758(90)90388-k.
Camargo, E. P., Kastelein, P., & Roitman, I. (1990). Trypanosomatid parasites of plants (phytomonas). Parasitology today (Personal ed.), 6(1), 22-5. https://doi.org/10.1016/0169-4758(90)90388-k
Camargo, E P, et al. "Trypanosomatid parasites of plants (phytomonas)." Parasitology today (Personal ed.) vol. 6,1 (1990): 22-5. doi: https://doi.org/10.1016/0169-4758(90)90388-k
Camargo EP, Kastelein P, Roitman I. Trypanosomatid parasites of plants (phytomonas). Parasitol Today. 1990 Jan;6(1):22-5. doi: 10.1016/0169-4758(90)90388-k. PMID: 15463252.
Copy Download .nbib Format: NLM
Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia : A Comparison with Gemfibrozil.

Clinical drug investigation

van Dam M, Stalenhoef AF, Wittekoek J, Trip MD, Prins MH, Kastelein JJ.
PMID: 27517547
Clin Drug Investig. 2001 Mar;21(3):175-81. doi: 10.2165/00044011-200121030-00003.

OBJECTIVES: To compare the effects of concentrated n-3 fatty acids (Omacor™) and gemfibrozil in patients with severe hypertriglyceridaemia. The primary objective was to measure the change in serum triglyceride (TG), and the secondary objectives were to study the changes...

Cite
van Dam M, Stalenhoef AF, Wittekoek J, et al. Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia : A Comparison with Gemfibrozil. Clin Drug Investig. 2001;21(3):175-81doi: 10.2165/00044011-200121030-00003.
van Dam, M., Stalenhoef, A. F., Wittekoek, J., Trip, M. D., Prins, M. H., & Kastelein, J. J. (2001). Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia : A Comparison with Gemfibrozil. Clinical drug investigation, 21(3), 175-81. https://doi.org/10.2165/00044011-200121030-00003
van Dam, M, et al. "Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia : A Comparison with Gemfibrozil." Clinical drug investigation vol. 21,3 (2001): 175-81. doi: https://doi.org/10.2165/00044011-200121030-00003
van Dam M, Stalenhoef AF, Wittekoek J, Trip MD, Prins MH, Kastelein JJ. Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia : A Comparison with Gemfibrozil. Clin Drug Investig. 2001 Mar;21(3):175-81. doi: 10.2165/00044011-200121030-00003. PMID: 27517547.
Copy Download .nbib Format: NLM
Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world.

Data in brief

Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B.
PMID: 27766290
Data Brief. 2016 Sep 29;9:616-620. doi: 10.1016/j.dib.2016.09.037. eCollection 2016 Dec.

Data presented here refer to 57,885 patients on lipid-lowering statin therapy from the Dyslipidaemia International Study (DYSIS) registry. Subjects were divided into 3 discrete subsets: those at very high-risk, high-risk, and non-high-risk for cardiovascular events, with assigned low density...

Cite
Gitt AK, Lautsch D, Ferrieres J, et al. Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world. Data Brief. 2016;9:616-620doi: 10.1016/j.dib.2016.09.037.
Gitt, A. K., Lautsch, D., Ferrieres, J., Kastelein, J., Drexel, H., Horack, M., Brudi, P., Vanneste, B., Bramlage, P., Chazelle, F., Sazonov, V., & Ambegaonkar, B. (2016). Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world. Data in brief, 9616-620. https://doi.org/10.1016/j.dib.2016.09.037
Gitt, Anselm K, et al. "Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world." Data in brief vol. 9 (2016): 616-620. doi: https://doi.org/10.1016/j.dib.2016.09.037
Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B. Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world. Data Brief. 2016 Sep 29;9:616-620. doi: 10.1016/j.dib.2016.09.037. eCollection 2016 Dec. PMID: 27766290; PMCID: PMC5066206.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 31 entries